TriaGen Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-12,620
Closed -$1.5M 182
2024
Q3
$1.5M Sell
12,620
-5,711
-31% -$762K 0.5% 55
2024
Q2
$2.62M Buy
18,331
+12,642
+222% +$1.68M 1.01% 25
2024
Q1
$730K Hold
5,689
0.3% 74
2023
Q4
$589K Buy
+5,689
New +$563K 0.28% 82

Other funds holding NVO

TriaGen Wealth Management's NVO Position: Q4 2024 in Review

TriaGen Wealth Management sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 12,620 shares — an estimated $1.5M sold.

TriaGen Wealth Management first reported a position in NVO in Q4 2023 and held it in 4 quarters. The position peaked at $2.62M in Q2 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • TriaGen Wealth Management reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • TriaGen Wealth Management sold 12,620 Novo Nordisk shares in Q4 2024, an estimated $1.5M.
  • TriaGen Wealth Management first reported a position in Novo Nordisk in Q4 2023 and held it in 4 quarters.
  • TriaGen Wealth Management's Novo Nordisk position peaked at $2.62M in Q2 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on TriaGen Wealth Management's 13F filing for Q4 2024, filed 23 Jan 2025.